Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aung Naing

Showing results (351-360 of 397) with videos related to

Pageof 40
Sort By:
Journal of Immunotherapy and Precision Oncology|February 17, 2025
Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I TrialMirella Nardo, Mohamed A Gouda, Matthew J Reilley, et al.
Cancer Medicine|February 13, 2025
A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell CarcinomaOmar Alhalabi, Mohamed A Gouda, Denái R Milton, et al.
Frontiers in Immunology|February 8, 2021
Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary ComplicationsSang T Kim, Ajay Sheshadri, Vickie Shannon, et al.
Molecular Cancer Research : MCR|December 16, 2020
Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient OutcomesOmar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
Journal for Immunotherapy of Cancer|October 24, 2020
Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom InventoryTito Mendoza, Ajay Sheshadri, Mehmet Altan, et al.
Journal for Immunotherapy of Cancer|June 24, 2026
Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumorsMohamed H Derbala, Bettzy Stephen, Woochan Hwang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2016
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid TumorsAung Naing, Kyriakos P Papadopoulos, Karen A Autio, et al.
NPJ Precision Oncology|October 27, 2022
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncologyHenry Hiep Vo, Siqing Fu, David S Hong, et al.
Cancer|July 6, 2022
Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort studyVinod Ravi, Aparna Subramaniam, Jing Zheng, et al.
Oncotarget|May 19, 2015
Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapiesFilip Janku, Philipp Angenendt, Apostolia M Tsimberidou, et al.
Pageof 40

Showing results (351-360 of 397) with videos related to

Sort By:
Pageof 40
Journal of Immunotherapy and Precision Oncology|February 17, 2025
Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I TrialMirella Nardo, Mohamed A Gouda, Matthew J Reilley, et al.
Cancer Medicine|February 13, 2025
A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell CarcinomaOmar Alhalabi, Mohamed A Gouda, Denái R Milton, et al.
Frontiers in Immunology|February 8, 2021
Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary ComplicationsSang T Kim, Ajay Sheshadri, Vickie Shannon, et al.
Molecular Cancer Research : MCR|December 16, 2020
Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient OutcomesOmar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
Journal for Immunotherapy of Cancer|October 24, 2020
Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom InventoryTito Mendoza, Ajay Sheshadri, Mehmet Altan, et al.
Journal for Immunotherapy of Cancer|June 24, 2026
Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumorsMohamed H Derbala, Bettzy Stephen, Woochan Hwang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2016
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid TumorsAung Naing, Kyriakos P Papadopoulos, Karen A Autio, et al.
NPJ Precision Oncology|October 27, 2022
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncologyHenry Hiep Vo, Siqing Fu, David S Hong, et al.
Cancer|July 6, 2022
Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort studyVinod Ravi, Aparna Subramaniam, Jing Zheng, et al.
Oncotarget|May 19, 2015
Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapiesFilip Janku, Philipp Angenendt, Apostolia M Tsimberidou, et al.
Pageof 40